PaxMedica, Inc. (PXMD)

Market Cap	63.13K -97.4%
Revenue (ttm)	n/a
Net Income	-13.49M
EPS	-1.91
Shares Out	126.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Average Volume	58,652
Open	0.0005
Previous Close	0.0005
Day's Range	0.0001 - 0.0005
52-Week Range	0.0000 - 0.0200
Beta	-38.20
RSI	53.25
Earnings Date	Mar 13, 2026

About PaxMedica

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: PXMD